We get up in arms about testosterone and HGH — substances our bodies naturally produce and which have few serious side effects or long-lasting consequences — because they’re on a banned list. Meanwhile there’s a drug that a lot of athletes take under the direction and supervision of their teams which can kill people and is banned in several countries: the anti-inflammatory Toradol.
Gordon Edes of ESPN Boston has a story about its use in baseball. The hook: an interview with Jonathan Papelbon who took it routinely when he was with the Red Sox but who was told by the Phillies that he can no longer take it as they do not allow it. Edes looks into the controversial drug, notes its serious side effects, which can include internal bleeding (Clay Buchholz believes it’s what led to him contracting esophagitis which landed him in the ICU) and notes that it’s banned in several countries, for athletes and normal folks alike.
Papelbon’s description of its use in Major League Baseball is pretty familiar-sounding: it’s taken before the game to help guys “get through a 162 game season.” It’s, by definition, a performance enhancing drug. It’s letting guys do things they otherwise couldn’t do. Allowing their bodies to recover faster which allows them to train harder and compete at a more intense level than they otherwise could. Except it’s not on a banned list so no one cares despite the fact that it has the potential to kill you.
There is a tremendous disconnect between the drugs people think are awful in sports and the drugs that truly have the potential to be harmful. This is maybe the best example. Might be nice if we thought about our priorities about these things once in a while.
Cubs’ manager Joe Maddon hasn’t selected a fifth starter for his 2017 rotation yet, but told reporters that he could envision left-handers Brett Anderson and Mike Montgomery sharing the spot throughout the year. Neither pitcher was stretched out to the full 200-inning threshold last year, Maddon added, and suggested that the two could alternate innings out of the rotation and bullpen as needed (via MLB.com’s Carrie Muskat).
Anderson, 29, was acquired by the Cubs in January on a $3.5 million deal. He’s coming off a rough 2016, during which he underwent back surgery and missed all but 11 1/3 innings of his last season with the Dodgers. His last full, healthy year in the majors yielded a 3.69 ERA, 2.3 BB/9 and 5.8 SO/9 over 180 1/3 innings with Los Angeles in 2015.
Montgomery, meanwhile, is vying for a rotation spot after pitching almost exclusively from the bullpen during the second half of the Cubs’ 2016 run. The 27-year-old lefty put up a 2.82 ERA, 4.7 BB/9 and 8.9 SO/9 over 38 1/3 innings for Chicago last year, returning in the postseason to post a 3.14 ERA during the Cubs’ championship finish.
Maddon also mentioned the possibility of throwing a sixth starter into the mix, which would help prevent his other starters from getting overworked too early in the year. Either way, Anderson and Montgomery are expected to get a lot of looks early in spring training as rotation spots are finalized in the weeks leading up to Opening Day.
Orioles’ center fielder Michael Bourn is expected to be sidelined for four weeks while he rehabs a broken ring finger on his right hand, according to reports from the Baltimore Sun’s Peter Schmuck. Bourn broke the finger while playing catch with a football after a spring training workout.
The veteran outfielder re-signed with the club earlier this week on a minor league deal and was prepared to compete for a bench role this season. He’s in line to receive a $2 million salary if he makes the major league roster and can make an additional $3.5 million in incentives based on a set number of plate appearances. Now, however, his chances of cracking the roster out of spring training look considerably diminished, as his current timetable gives him an approximate return date of March 25 if all goes well.
Bourn had an impressive, if short-lived run with the Orioles following his trade to Baltimore last August, batting .283/.358/.435 with two home runs and a .793 OPS in 55 PA. While still somewhat removed from the totals that brought him an All-Star nod with the Braves in 2012, his defensive chops should give the Orioles some depth in center once he’s healthy again.